Rate This:Top Multiple Myeloma Treatment Options
Advancements in treatment options for multiple myeloma are giving patients more reasons to be optimistic. There are now five classes of medications that all treat this serious form of cancer in their own ways. Here, we'll review the top multiple myeloma treatment options from these important families of medications. Learn more about how these treatments work and the side effects associated with each class. Additional treatments are currently being researched to combat this cancer that begins in malignant plasma cells, but already patients have more options to choose from than they did just 10 years ago. Read on for more information about the top multiple myeloma treatment options.8 Active Questions | Add a Question
Darzalex is available in generic form as daratumumab, and Empliciti is available in generic form as elotuzumb. Pomalyst is available in generic form as pomalidomide, and Revlimid is available in generic form as lenalidomide. Kyprolis is available in generic form as carfilzomib, and Ninlaro is available in generic from as ixazombib.
The top three treatment options we'll review in detail are three important classes of medications. They are monoclonal antibodies, immunomodulatory drugs and proteasome inhibitors.
Monoclonal antibodies are artificial proteins that mirror the body's natural proteins used to hunt down and destroy infections cells. These man-made antibodies are designed to target specific proteins found on the surfaces of multiple myeloma cells.
Darzalex and Empliciti are the two available monoclonal antibodies. Common side effects of these medications include fatigue, back pain, coughing and nausea. Rare, serious side effects include difficulty breathing, tightness in the throat and wheezing.
Immunomodulatory drugs bolster the body's immune system to target and attack multiple myeloma cells, but researchers aren't exactly sure how these treatments work. They can only be obtained through special programs from their manufacturers.
Pomalyst and Revlimid are two of the drugs belonging to this class of medications. Serious side effects associated with these medications include blood clots and nerve damage; Pomalyst is more likely to cause clots but less likely to cause nerve damage.
Proteasome inhibitors interrupt the reproduction of cancer cells to slow the spread of multiple myeloma, and they're especially effective in slowing the growth of tumors.
Kyprolis and Ninlaro are two proteasome inhibitors. Of the two, most patients will be prescribed Kyprolis first. Ninlaro is more of a last-resort proteasome inhibitor that's recommended when other medications fail to produce satisfactory results. Common side effects of these medications include diarrhea and nausea; these medications can also cause complications from lowering platelet counts.